AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04809467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
Study NCT06570525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NurseNET
Description: Nurse-Delivered Narrative Exposure Therapy (NurseNET). Narrative Exposure Therapy (NET) is a brief, low-cost, trauma-focused treatment modality that is effective in treating mobile populations with complex PTSD. In NurseNET, NET is facilitated by a clinically experienced nurse, while peers/program support specialists offer scaffolded support, fostering trust, engagement, and retention. NurseNET begins with administration of a diagnostic battery and psychoeducation. Then, in subsequent NurseNET sessions, using gradual imaginative exposure, the nurse guides the participant to verbally express and re-frame their personal trauma narratives to shift unhelpful beliefs/symptoms around trauma. NurseNET utilizes a racism-conscious approach to create relational spaces in which narratives of WEH are positioned to challenge dominant social narratives. Each NurseNET session offers a brief soulfulness-based stress reduction activity to prompt emotional/affective grounding.
Study NCT06570525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAL
Description: Peer Active Listening (PAL). In the PAL active comparator/control, peers/program support specialists meet individually with participants in active listening sessions, along the same visit sequence as NurseNET. During PAL sessions, peers/program support specialists allow participants to set each conversational agenda while practicing the tenets of active listening, including attending to body language, paraphrasing the participant's verbal expressions, reflecting feelings, and using tactful repetition. PAL sessions are not intended to center on topics of trauma, but rather designed to offer a supportive relationship (attentional control).
Study NCT05975775 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic radical prostatectomy
Description: Prostate cancer may require laparoscopic radical prostatectomy, a surgical procedure performed under general anaesthetic.
Study NCT04510857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOVE-IT Intervention
Description: The MOVE-IT device comprises a custom smart toy and therapy game software to enable repetitive task practice involving the arm and hand.
Study NCT04510857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UCT Control
Description: Participants assigned to the UCT control group will continue to receive their previously prescribed therapy services.
Study NCT05677126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tralement
Description: Tralement with Manganese
Study NCT05677126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose trace element combination product of zinc, copper, and selenious acid
Description: Tralement without Manganese
Study NCT05973851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine Nasal Product
Description: See arm description
Study NCT05973851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: See arm description
Study NCT05973851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: See arm description
Study NCT05973851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line Antidepressants
Description: See arm description
Study NCT04330846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
Study NCT05743764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU007
Description: cyclosporine 0.02%, trehalose 3%
Study NCT05743764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: cyclosporine 0.05%
Study NCT05743764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moisview Eye drop
Description: trehalose 3%
Study NCT05415202 — intervention group
Intervention type: DRUG
Intervention: Remimazolam 20 MG [Byfavo]
Description: Remimazolam will be administered for sedation and efficacy and safety will be recorded
Study NCT04993027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Powder
Description: Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
Study NCT04705597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-175
Description: Drug
Study NCT04705597 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05387395 — intervention group
Intervention type: OTHER
Intervention: NO intervention
Description: no intervention
Study NCT04560907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aquablation
Description: By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary.~Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated.
Study NCT04560907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HoLEP
Description: This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
Study NCT06018428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-914
Description: Subcutaneous administration of ADX-914
Study NCT06018428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration of placebo
Study NCT05163561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A
Description: SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
Study NCT05163561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B
Description: SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
Study NCT05163561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C
Description: SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
Study NCT05163561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sii Licensed IPV
Description: Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.
Study NCT05421039 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exposure to unintended injuries
Description: After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers
Study NCT05452564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
Study NCT06533215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.
Description: The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml).
Study NCT06515249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine
Description: Integrative medicine treatments including acupuncture, touch, movement, mind-body, as patient\&#39;s and staff\&#39;s choice
Study NCT06522412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: JING SI HERBAL TEA LIQUID PACKETS
Description: JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.
Study NCT06522412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JING SI HERBAL TEA LIQUID PACKETS
Description: JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.
Study NCT06522412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: JING SI HERBAL TANG HENG POWDER DRINK
Description: JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).
Study NCT06522412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JING SI HERBAL TANG HENG POWDER DRINK
Description: JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).
Study NCT05876260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Greek yogurt
Description: Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
Study NCT05876260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-based study supplement
Description: Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
Study NCT05876260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
Study NCT05876260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
Study NCT06328075 — intervention group
Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study
Study NCT05099757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: one-dose, two-dose or three-dose, 20 µg per dose
Study NCT06385262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 300 mg subcutaneously every 4 weeks prior to surgery
Study NCT06385262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350mg IV every 3 weeks prior to surgery
Study NCT06385262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
Study NCT05053139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
Study NCT05500508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT1501
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules
Study NCT05500508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.
Study NCT05690828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
Study NCT04646460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observed Success
Description: The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain.
Study NCT04646460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observed Failure
Description: The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
Study NCT05023720 — intervention group
Intervention type: OTHER
Intervention: nonintervention
Study NCT04646460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experienced Success
Description: The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.
Study NCT04646460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experienced Failure
Description: The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.
Study NCT06026254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
Study NCT06026254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitor
Description: Administered according to product label
Study NCT04913259 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Remote monitoring
Description: Online remote monitoring tool during the care of patients over the age of 65 who are receiving medical treatment for cancer
Study NCT05953740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5720
Description: MK-5720 IM injection
Study NCT05953740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-5720
Description: Placebo matched to MK-5720 IM injection
Study NCT05953740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 tablet taken by mouth
Study NCT05953740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-8189
Description: Placebo tablet matched to MK-8189
Study NCT04965831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.
Study NCT06627855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial Distortion Model
Description: The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
Study NCT06627855 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The techniques in the therapy will be applied by imitating the techniques in the therapy for the fascial distortions determined according to the Manual Therapy Based on the Fascial Distortion Model.
Study NCT06472791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Centella Asiatica
Description: Centella Asiatica is a perennial, herbaceous plant that is sold as a dietary supplement in the United States under the name Gotu Kola. It has been used for centuries in Ayurvedic and Chinese medicine. Evidence suggests it may help with resilience to aging and cognitive decline. The product for this study will be produced by Arjuna Natural.
Study NCT06472791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The comparator will contain microcystalline cellulose in matched capsules. The comparator product for this study will be produced by Arjuna Natural.
Study NCT05668507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACHOUT Virtual Mental Health Support
Description: REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~1. One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~2. Group support delivered via a 24/7 chat room~3. Face to face support delivered via virtual happy hours
Study NCT04409418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extended dwell catheters
Description: EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
Study NCT04409418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended dwell catheters
Description: EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
Study NCT06456684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluoro[18F]promethazine
Description: It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease
Study NCT05379023 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face-to-face evaluation (FF)
Description: The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
Study NCT05658640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral
Study NCT05658640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral/ Intravenous